Literature DB >> 19216840

VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.

C Lance Cowey1, W Kimryn Rathmell.   

Abstract

The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19216840      PMCID： PMC2873025          DOI： 10.1007/s11912-009-0015-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  45 in total

1.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Authors:  M S Wiesener; P M Münchenhagen; I Berger; N V Morgan; J Roigas; A Schwiertz; J S Jürgensen; G Gruber; P H Maxwell; S A Löning; U Frei; E R Maher; H J Gröne; K U Eckardt
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 2.  The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.

Authors:  Daniel Cho; Sabina Signoretti; Meredith Regan; James W Mier; Michael B Atkins
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

Authors:  Jung Han Kim; Chul Won Jung; Yeon Hee Cho; Jeeyun Lee; Se-Hoon Lee; Ho Young Kim; Jinny Park; Joon-Oh Park; Kihyun Kim; Won Seog Kim; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Keunchil Park
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

6.  Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.

Authors:  B Zbar; T Kishida; F Chen; L Schmidt; E R Maher; F M Richards; P A Crossey; A R Webster; N A Affara; M A Ferguson-Smith; H Brauch; D Glavac; H P Neumann; S Tisherman; J J Mulvihill; D J Gross; T Shuin; J Whaley; B Seizinger; N Kley; S Olschwang; C Boisson; S Richard; C H Lips; M Lerman
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 8.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.

Authors:  Jean-Jacques Patard; Patricia Fergelot; Pierre I Karakiewicz; Tobias Klatte; Quoc-Dien Trinh; Nathalie Rioux-Leclercq; Jonathan W Said; Arie S Belldegrun; Allan J Pantuck
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

10.  Promoter hypermethylation profile of kidney cancer.

Authors:  Essel Dulaimi; Inmaculada Ibanez de Caceres; Robert G Uzzo; Tahseen Al-Saleem; Richard E Greenberg; Thomas J Polascik; James S Babb; William E Grizzle; Paul Cairns
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531
View more
  56 in total

Review 1.  Emerging molecular classification in renal cell carcinoma: implications for drug development.

Authors:  Kathryn E Hacker; W Kimryn Rathmell
Journal:  Target Oncol       Date:  2010-07-20       Impact factor: 4.493

Review 2.  Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers.

Authors:  Jordan M Thompson; Jaime Landman; Olga V Razorenova
Journal:  Small GTPases       Date:  2017-07-07

3.  Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.

Authors:  Daniel M Tennenbaum; Brandon J Manley; Emily Zabor; Maria F Becerra; Maria I Carlo; Jozefina Casuscelli; Almedina Redzematovic; Nabeela Khan; Maria E Arcila; Martin H Voss; Darren R Feldman; Robert J Motzer; Nicole E Benfante; Jonathan A Coleman; Paul Russo; James J Hsieh; Abraham Ari Hakimi
Journal:  Urol Oncol       Date:  2017-04-10       Impact factor: 3.498

4.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

Review 5.  Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Authors:  Matthew K Labriola; Kristen A Batich; Jason Zhu; Megan A McNamara; Michael R Harrison; Andrew J Armstrong; Daniel J George; Tian Zhang
Journal:  Clin Genitourin Cancer       Date:  2019-02-05       Impact factor: 2.872

6.  HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.

Authors:  Hilary E Nicholson; Zeshan Tariq; Benjamin E Housden; Rebecca B Jennings; Laura A Stransky; Norbert Perrimon; Sabina Signoretti; William G Kaelin
Journal:  Sci Signal       Date:  2019-10-01       Impact factor: 8.192

Review 7.  Basic research in kidney cancer.

Authors:  Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun
Journal:  Eur Urol       Date:  2011-07-05       Impact factor: 20.096

8.  Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Authors:  Kevin D Courtney; Jeffrey R Infante; Elaine T Lam; Robert A Figlin; Brian I Rini; James Brugarolas; Naseem J Zojwalla; Ann M Lowe; Keshi Wang; Eli M Wallace; John A Josey; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2017-12-19       Impact factor: 44.544

Review 9.  Epigenetic plasticity and the hallmarks of cancer.

Authors:  William A Flavahan; Elizabeth Gaskell; Bradley E Bernstein
Journal:  Science       Date:  2017-07-21       Impact factor: 47.728

10.  Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis.

Authors:  Steffen Rausch; Johanna Beermann; Marcus Scharpf; Jörg Hennenlotter; Falko Fend; Arnulf Stenzl; Daniel Schollenberger; Jens Bedke; Stephan Kruck
Journal:  World J Urol       Date:  2016-03-19       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.